APA (7th ed.) Citation

Ramalingam, S. S., Jänne, P. A., Mok, T., O'Byrne, K., Boyer, M. J., Von Pawel, J., . . . Paz-Ares, L. (2014). Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial. Lancet Oncology, 15(12), 1369. https://doi.org/10.1016/S1470-2045(14)70452-8

Chicago Style (17th ed.) Citation

Ramalingam, Suresh S., et al. "Dacomitinib Versus Erlotinib in Patients with Advanced-stage, Previously Treated Non-small-cell Lung Cancer (ARCHER 1009): A Randomised, Double-blind, Phase 3 Trial." Lancet Oncology 15, no. 12 (2014): 1369. https://doi.org/10.1016/S1470-2045(14)70452-8.

MLA (9th ed.) Citation

Ramalingam, Suresh S., et al. "Dacomitinib Versus Erlotinib in Patients with Advanced-stage, Previously Treated Non-small-cell Lung Cancer (ARCHER 1009): A Randomised, Double-blind, Phase 3 Trial." Lancet Oncology, vol. 15, no. 12, 2014, p. 1369, https://doi.org/10.1016/S1470-2045(14)70452-8.